Menin inhibitors for adult acute myeloid leukemia: 2025 update
Menin inhibitor approval/use is expanding into other <i>HOX-</i>driven subtypes (e.g. <i>NPM1, NUP98r</i>), as a frontline option and in combination settings. Monitoring for differentiation syndrome, QT interval prolongation, recognizing pseudo-progression, and supportive care needs remains essential to maximize patient benefit.
Authors
- Umar Iqbal (ORCID: https://orcid.org/0000-0002-3049-4094)
- D. Sallman
- Rory Michael Shallis (ORCID: https://orcid.org/0000-0002-8542-2944)
- Julia Fadul (ORCID: https://orcid.org/0009-0001-0694-266X)
Institutions
- Moffitt Cancer Center (US)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1080/13543784.2025.2612321
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00